论文部分内容阅读
作者自１９９３年１月采用口服ＶＰ１６联合ＤＤＰ方案治疗非小细胞肺癌（ＮＳＣＬＣ）３５例，所有病例均由组织学检查证实。结果ＣＲ１例、ＰＲ１６例、Ｓ８例、Ｐ１０例，有效率（ＣＲ＋ＰＲ）４８．６％。全组中位生存期９．８个月。恶心、呕吐发生率为７８．３％，粘膜炎为１０．４％，白细胞和血小板降低发生率分别为５８．１％和１５．２％，大多为轻、中度。作者认为ＶＰ１６对小细胞肺癌（ＳＣＬＣ）的疗效有显著的时间依赖性，长时间、低剂量口服ＶＰ１６对ＳＣＬＣ有较好的疗效，但对ＮＳＣＬＣ的疗效是否更好，本文尚未证明。然而，方便给药，利于门诊化疗是其优点。
The authors treated 35 patients with non-small cell lung cancer (NSCLC) with oral VP16 combined with DDP regimen in January 1993. All cases were confirmed by histological examination. Results CR1 cases, PR16 cases, S8 cases, P10 cases, effective rate (CR + PR) 48.6%. The median survival time for the whole group was 9.8 months. The incidence of nausea and vomiting was 78.3%, mucositis was 10.4%, and the incidence of white blood cell and platelet reduction was 58.1% and 15.2%, respectively. Most of them were mild to moderate. The authors believe that VP16 has a significant time-dependent effect on the efficacy of small cell lung cancer (SCLC). Long-term, low-dose oral VP16 has a good effect on SCLC, but whether the efficacy of NSCLC is better, this article has not yet proved. However, convenient administration is beneficial to outpatient chemotherapy.